Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

November 14, 2013.  Interested parties can access the replay by dialing 888-843-7419 or 630-652-3042 internationally and entering the conference number 35977176.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Saturday, December 7, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future development and therapeutic potential of quizartinib and Ambit's other drug candidates, progress and timing o
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Chester, OH (PRWEB) November 25, 2014 ... Holdings, has joined the Graphel Carbon Products team as ... in sales, marketing, and customer service for the graphite ... add Miles to our team,” stated Dave Trinkley, VP ... “His wide range of experience in the graphite ...
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation ... sur le marché européen au salon Hi Europe ... Amsterdam ). Curcumine la plus ... technologie amorphe (non-cristalline) à des ingrédients approuvés par ... un pigment jaune présent dans la racine de ...
(Date:11/24/2014)... BUENA, N.J. , Nov. 24, 2014  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... submissions in 2014 to seven, with eighteen submissions now ... Grenfell-Gardner , President and CEO of the Company, commented, ...
(Date:11/24/2014)... November 24, 2014   ... ScienceDirect   Elsevier , a world-leading provider ... pleased to announce the launch of the latest title in ... Current Opinion in Food Science . ... specialists with a new platform to keep up-to-date with the ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3IGI Laboratories, Inc. Announces ANDA Submission 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... Brings Both Clinical Trial Experience and Business ... Role, CAMBRIDGE, Mass., Jan. 16 Cytel, ... executive Irving Dark has,accepted the role of Vice ... to Cytel 15-years of management experience guiding drug,biologic ...
... BASEL, Switzerland, Jan. 16 Roche (OTCQX:,RHHBY; SWX: ROG.VX; ... today that it has extended its,offer to acquire all ... (Nasdaq: VMSI ) to 5:00 p.m., New York ... was previously scheduled to expire at 5:00,p.m., New York ...
... NEW YORK, Jan. 16 With the field ... research, the Society for Biological Engineering,(SBE) has organized ... conference, which runs from January 20th to 23rd ... will focus on,engineering designs for stem cell production, ...
Cached Biology Technology:Irving Dark Named Vice President of Cytel Clinical Research Services 2Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Roche Extends Tender Offer for Ventana 5Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2
(Date:11/4/2014)... 4, 2014   Neurotechnology , a provider ... the latest version of its fingerprint matching algorithm ... MINEX evaluation organized by NIST. The MINEX ... the INCITS 378 fingerprint standard template format. MINEX ... tenders in the United States ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... who have adapted a three-dimensional, general circulation model of ... ago when the sun was significantly fainter than present ... catastrophic glaciation than previously believed. The new 3-D ... from about 3.8 billion years to 2.5 billion years ...
... Managing commercial and recreational fisheries is a complex ... and regulatory agencies don,t always see eye-to-eye. Researchers ... now working with commercial fishermen to collect and share ... build trust and foster the mutual goal of sustainable ...
... neurodegenerative diseases such as Parkinson,s and Alzheimer,s, cancer and ... partially caused or accelerated by oxidative stress. Oxidative stress ... what are called reactive oxygen species (ROS). "However, up ... changes in a living organism and certainly not how ...
Cached Biology News:Early Earth may have been prone to deep freezes, says CU-Boulder study 2Early Earth may have been prone to deep freezes, says CU-Boulder study 3Public-private partnership helps monitor fish populations 2Public-private partnership helps monitor fish populations 3Public-private partnership helps monitor fish populations 4Public-private partnership helps monitor fish populations 5Oxidative stress: Less harmful than suspected? 2
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Preparation Note: Prepared by a ... C.W., et al., Biotechnol. Bioeng., ... Definition: One unit will yield an ... 1.0 ml of water (1 cm ...
... Dithiothreitol DTT White solid.. ... disulfides to thiols, so reaction is "driven" to ... not contain waxy surfactant found in many other ... pentobarbitol. Purity: ≥97% by titration. ...
... Basically, most ``special`` dye stains are ... few other non-routine) stains are $9.00. ... a paraffin block, staining, coverslipping and ... (for senile plaques) ,Bodian`s Stain ,Copper ...
Biology Products: